![PE132010: β-GalNAc-PEG3-Acid label-new / β-Glc-PEG3-NH-Fmoc / 2-{2-[2-N-(Fluoren-9-yl-methoxycarbonyl aminoethoxy)]ethoxy}ethyl](https://cdn.shopify.com/s/files/1/0810/4889/5786/files/PE132010-R_d936f257-4d84-431f-b1c7-8303bd5681ac.svg?v=1700576679)
Pay in 4 interest-free payments of $43.75 Learn more
Ships within 48 hours · Estimated delivery Oct 25 - Oct 30
/ β-Glc-PEG3-NH-Fmoc / 2-{2-[2-N-(Fluoren-9-yl-methoxycarbonyl aminoethoxy)]ethoxy}ethyl β-D-glucopyranoside
Fmoc-L-Ser(GlcNAcβ(1-3)GalNAc)-OH (Peracetate)
used to synthesize peptides modeling early non-enzymatic glycation
/ β-D-GalNAc-Hexyl-Amine / β-D-GalNAc-Hex-NH2
C34H31D4NO10S / 653
PE132010: β-GalNAc-PEG3-Acid label-new / β-Glc-PEG3-NH-Fmoc / 2-{2-[2-N-(Fluoren-9-yl-methoxycarbonyl aminoethoxy)]ethoxy}ethylC15H27NO10 381. 38 A D N acetylgalactosamine (GalNAc) ligand equipped with a terminal carboxylic acid through a hydrophilic PEG3 spacer. The carboxylic acid can be activated to NHS, sulfo NHS, or pentafluorophenyl esters and reacted with amine functionalized platforms or lysine residues on proteins and peptides to form amide bonds. This compound enables the construction of hepatocyte targeted therapeutics and research tools that exploit the
US$ 77.02
US$ 31.25
US$ 108.60
US$ 47.10
US$ 115.67
US$ 137.72
